Portal de Periódicos da CAPES

Use of Depot Medroxyprogesterone Acetate and Fracture Risk

2010; Oxford University Press; Volume: 95; Issue: 11 Linguagem: Inglês

10.1210/jc.2010-0032

1945-7197

Christian Meier, Yolanda B. Brauchli, Susan S. Jick, Marius Kraenzlin, Christoph Meier,

Bone health and treatments

Context: Depot medroxyprogesterone acetate (DMPA), which has a high rate of use among teenagers in Europe and the United States, has been associated with impaired bone mineral acquisition during adolescence and accelerated bone loss in later life. Studies on the association between DMPA use and fracture risk are limited.